Inhibitory receptor agonists: Emerging strategies in immune modulation

Area of Science:

• Immunology
• Immunotherapy
• Autoimmunity

Background:

• Inhibitory receptors (IRs) like CTLA-4, PD-1, LAG3, TIM-3, and TIGIT regulate immune homeostasis and prevent autoimmunity.
• IR blockade revolutionized cancer immunotherapy by enhancing anti-tumor T cell responses.
• Emerging strategies explore harnessing IRs for autoimmune and inflammatory diseases.

Purpose of the Study:

• To review recent advancements in agonistic IR-targeted therapies for autoimmune and inflammatory disorders.
• To examine the mechanisms of action, efficacy, and translational challenges of these novel therapies.

Main Methods:

• Literature review of preclinical and clinical studies on agonistic IR antibodies.
• Analysis of IR signaling pathways and their role in immune tolerance.
• Evaluation of therapeutic efficacy in autoimmune disease models.

Main Results:

• Agonistic IR antibodies promote immune tolerance and suppress pathological T cell functions in preclinical models.
• These therapies demonstrate potential for managing autoimmunity and inflammation.
• Significant translational challenges remain for clinical application.

Conclusions:

• Agonistic IR-targeted therapies represent a promising frontier for treating autoimmune and inflammatory conditions.
• Further research and clinical development are needed to overcome translational hurdles.
• Harnessing IRs offers a novel approach to immune modulation in disease management.